Nacuity Pharmaceuticals, Inc. is a clinical stage pharmaceutical company whose mission is to develop a breakthrough treatment for retinitis pigmentosa (“RP”) and potentially other ophthalmological indications. Our lead technology is based on studies from the laboratory of Dr. Peter Campochiaro at the Wilmer Eye Institute involving oxidative stress in the retina.
Nacuity has assembled an accomplished team and has received significant financial and technical support from the Foundation Fighting Blindness (FFB). The mission of FFB is to drive research providing prevention, treatments and cures for people affected by blinding retinal diseases. Over the last nearly 50 years, FFB has invested over $700 million in this effort. FFB is a significant supporter of Dr. Campochiaro’s research and has committed to fund a substantial portion of Nacuity’s Phase 1 and Phase 2 trials through a milestone-based matching program grant to Nacuity in support of our NPI-001 development program.